Sarah Godfrey
8 December 2016

Deutsche Beteiligungs – DBAG Fund VI final investment; DBAG Fund VII investment period starts

Public offers of portfolio holdings at significant upside to carrying values


Swiss-listed healthcare investment specialist HBM Healthcare Investments (HBMN) has seen a material increase in NAV from the initial public offerings of two of its private portfolio holdings, ObsEva and Anaptys Biosciences. Both companies listed on the US NASDAQ exchange on 26 January.

Read more...
Sarah Godfrey
8 November 2016

Deutsche Beteiligungs announces divestment of Grohmann Engineering to Tesla Motors

Public offers of portfolio holdings at significant upside to carrying values


Swiss-listed healthcare investment specialist HBM Healthcare Investments (HBMN) has seen a material increase in NAV from the initial public offerings of two of its private portfolio holdings, ObsEva and Anaptys Biosciences. Both companies listed on the US NASDAQ exchange on 26 January.

Read more...
Sarah Godfrey
27 October 2016

Deutsche Beteiligungs proposes €1.20 per share dividend for FY16

Public offers of portfolio holdings at significant upside to carrying values


Swiss-listed healthcare investment specialist HBM Healthcare Investments (HBMN) has seen a material increase in NAV from the initial public offerings of two of its private portfolio holdings, ObsEva and Anaptys Biosciences. Both companies listed on the US NASDAQ exchange on 26 January.

Read more...
Sarah Godfrey
5 January 2017

European Assets Trust declares dividend for 2017

Public offers of portfolio holdings at significant upside to carrying values


Swiss-listed healthcare investment specialist HBM Healthcare Investments (HBMN) has seen a material increase in NAV from the initial public offerings of two of its private portfolio holdings, ObsEva and Anaptys Biosciences. Both companies listed on the US NASDAQ exchange on 26 January.

Read more...
Sarah Godfrey
25 October 2016

HarbourVest Global Private Equity consolidates listing in London

Public offers of portfolio holdings at significant upside to carrying values


Swiss-listed healthcare investment specialist HBM Healthcare Investments (HBMN) has seen a material increase in NAV from the initial public offerings of two of its private portfolio holdings, ObsEva and Anaptys Biosciences. Both companies listed on the US NASDAQ exchange on 26 January.

Read more...
Sarah Godfrey
31 January 2017

HBM Healthcare Investments: two IPOs and Q316/17 results

Public offers of portfolio holdings at significant upside to carrying values


Swiss-listed healthcare investment specialist HBM Healthcare Investments (HBMN) has seen a material increase in NAV from the initial public offerings of two of its private portfolio holdings, ObsEva and Anaptys Biosciences. Both companies listed on the US NASDAQ exchange on 26 January.

Read more...
Sarah Godfrey
6 December 2016

Standard Life European Private Equity Trust - changes to investment policy, dividend policy & fees

Public offers of portfolio holdings at significant upside to carrying values


Swiss-listed healthcare investment specialist HBM Healthcare Investments (HBMN) has seen a material increase in NAV from the initial public offerings of two of its private portfolio holdings, ObsEva and Anaptys Biosciences. Both companies listed on the US NASDAQ exchange on 26 January.

Read more...
Sarah Godfrey
23 December 2016

Tetragon Financial Group adopts IFRS reporting from 31 December 2016

Public offers of portfolio holdings at significant upside to carrying values


Swiss-listed healthcare investment specialist HBM Healthcare Investments (HBMN) has seen a material increase in NAV from the initial public offerings of two of its private portfolio holdings, ObsEva and Anaptys Biosciences. Both companies listed on the US NASDAQ exchange on 26 January.

Read more...
Sarah Godfrey
11 November 2016

Tetragon Financial Group commences US$50m tender offer

Public offers of portfolio holdings at significant upside to carrying values


Swiss-listed healthcare investment specialist HBM Healthcare Investments (HBMN) has seen a material increase in NAV from the initial public offerings of two of its private portfolio holdings, ObsEva and Anaptys Biosciences. Both companies listed on the US NASDAQ exchange on 26 January.

Read more...
Sarah Godfrey
28 October 2016

Tetragon Financial Group declares US$0.1675 per share Q316 dividend

Public offers of portfolio holdings at significant upside to carrying values


Swiss-listed healthcare investment specialist HBM Healthcare Investments (HBMN) has seen a material increase in NAV from the initial public offerings of two of its private portfolio holdings, ObsEva and Anaptys Biosciences. Both companies listed on the US NASDAQ exchange on 26 January.

Read more...
Sarah Godfrey
19 January 2017

The Merchants Trust announces benchmark change

Public offers of portfolio holdings at significant upside to carrying values


Swiss-listed healthcare investment specialist HBM Healthcare Investments (HBMN) has seen a material increase in NAV from the initial public offerings of two of its private portfolio holdings, ObsEva and Anaptys Biosciences. Both companies listed on the US NASDAQ exchange on 26 January.

Read more...
Sarah Godfrey
28 October 2016

VinaCapital Vietnam Opportunity Fund announces full-year results to 30 June

Public offers of portfolio holdings at significant upside to carrying values


Swiss-listed healthcare investment specialist HBM Healthcare Investments (HBMN) has seen a material increase in NAV from the initial public offerings of two of its private portfolio holdings, ObsEva and Anaptys Biosciences. Both companies listed on the US NASDAQ exchange on 26 January.

Read more...
Sarah Godfrey
7 December 2016

Witan revises performance benchmark weightings from 2017

Public offers of portfolio holdings at significant upside to carrying values


Swiss-listed healthcare investment specialist HBM Healthcare Investments (HBMN) has seen a material increase in NAV from the initial public offerings of two of its private portfolio holdings, ObsEva and Anaptys Biosciences. Both companies listed on the US NASDAQ exchange on 26 January.

Read more...